A novel topical gel, LUT014 (Lutris Pharma), significantly reduced the severity of the acne-like rash, a common side effect of anti-EGFR (epidermal growth factor receptor) therapies, in patients with colorectal cancer, according to a phase 2 trial.
The study, by researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center, was presented at the 2025 annual meeting of the American Association for Cancer Research,